Real-World Dermatology Visit In Moderate To Severe Plaque Psoriasis Patients Treated With Biologics Or Apremilast

Adult PsO patients newly initiating APR or a biologic from 01/01/2015 to 08/31/2018 with ≥1 dermatology visit were included. Index date was at the first claim of APR/biologic. Eligible patients had no prior use of index medication, and had continuous medical and pharmacy benefit over the 12 months pre-index and 24-months post-index. The number of dermatology visits and average days between visits were examined over the 24 months post-index by each index medication, and by treatment patterns. 5820 patients were included: SEC, 217; ADA, 1892; UST, 769; ETA, 690; and APR, 2252. The average number of dermatology visits over the 24 months post-index was 6.5 (SEC, 7.5; ADA, 5.4; UST, 7.0; ETA, 5.1; and APR, 7.7) and the frequency decreased from 3.6 in year 1 to 2.9 in year 2. Median time between visits was 111.8 days (SEC, 117.4; ADA, 117.9; UST, 89.6; ETA, 116.2; and APR, 115.0). 18.5% of patients had a dermatology visit in <2-month intervals, 49.8% in every 2-5 months, and 31.7% in ≥5 months. APR patients visited more often (